Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma

Journal: Nature Medicine

Published: 2019-02-11

DOI: 10.1038/s41591-018-0337-7

Affiliations: 19

Authors: 30

Go to article
Institutions FC
Center for Neuro-Oncology, DFCI, United States of America (USA) 0.13
UCLA Department of Neurosurgery, United States of America (USA) 0.11
UCLA Jonsson Comprehensive Cancer Center (JCCC), United States of America (USA) 0.09
UCLA Department of Biostatistics, United States of America (USA) 0.08
Department of Neurology, MSKCC, United States of America (USA) 0.07
UCSF Department of Neurological Surgery, United States of America (USA) 0.07
Department of Neuro-Oncology, MD Anderson Cancer Center, United States of America (USA) 0.07
Adaptive Biotechnologies LLC, United States of America (USA) 0.07
UCLA Department of Pediatrics, United States of America (USA) 0.05
UCLA Department of Neurology, United States of America (USA) 0.04
UCLA Department of Molecular and Medical Pharmacology (DMMP), United States of America (USA) 0.04
UCLA Department of Pathology and Laboratory Medicine, United States of America (USA) 0.03
Department of Neurosurgery, Utah, United States of America (USA) 0.03
Huntsman Cancer Institute at the University of Utah (HCI), Utah, United States of America (USA) 0.03
UCLA Division of Dermatology, United States of America (USA) 0.03
UCLA Department of Radiology, United States of America (USA) 0.02
Department of Neurology, MGH, United States of America (USA) 0.02
Cancer Center, MGH, United States of America (USA) 0.02
Parker Institute for Cancer Immunotherapy, United States of America (USA) 0.01

Return